Investigational Drug Dasotraline Significantly Improved Symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in a Placebo-Controlled Study in Adults
Posted Factbook 2014 ver.2
"Corporate profile" An English version and a Japanese version are updated.
Sumitomo Dainippon Pharma obtains Approval in Japan for Partial Change of the Approved Indication to “Type 2 Diabetes” for SUREPOST, a Rapid-acting Insulin Secretagogue
Posted Video for Second Quarter Financial Results for FY2014 [Webcast]
Sumitomo Dainippon Pharma Announces Organizational Realignment, and Changes in Executive Officers and Other Key Positions
A Message from the President
Board of Directors and Executive Officers